Physician profile
Robert Edward Stapleton
NPI 1295154623
$1,243.14
in general payments reported to CMS, 2019-2025
16 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.67 · 2023: $577 · 2024: $320 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.45 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $160.71 | 2023-2025 | |
| Glaxosmithkline, LLC. | $98.57 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $90.73 | 2024-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $88.20 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $55.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $47.91 | 2023 | |
| Merck Sharp & Dohme LLC | $41.52 | 2023 | Dificid |
| Becton, Dickinson and Company | $35.57 | 2025 | Bd Veritor Plus Analyzer |
| Astellas Pharma US INC | $23.13 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $21.68 | 2024 | Voquezna |
| Coloplast Corp | $20.82 | 2025 | |
| Amgen INC. | $19.79 | 2024 | Otezla, Repatha |
| Corium, LLC | $14.24 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $13.42 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.